Health&Life Co

Health&Life Co Capital Intensity

The Capital Intensity Ratio of Health&Life Co (1781.TWO) as of Nov 6, 2026 is 181.67 %. In the previous year, Capital Intensity Ratio was 115.70 % — a change of 57.02% (higher).

Capital Intensity

181.67 %

YoY

57.02%

Last updated:

Capital Intensity Ratio of Health&Life Co is 2025 181.67 % . Capital Intensity Ratio of Health&Life Co was 2024 115.70 % . It decreases by 57.02% higher compared to the previous year.

The Health&Life Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
96.54 TWD
Jan 1, 2019
135.41 TWD
Jan 1, 2020
130.34 TWD
Jan 1, 2021
95.63 TWD
Jan 1, 2022
100.28 TWD
Jan 1, 2023
118.23 TWD
Jan 1, 2024
115.70 TWD
Jan 1, 2025
181.67 TWD
The Health&Life Co Capital Intensity history
YEARCapital IntensityYoY
181.67 %+57.02%
115.70 %-2.15%
118.23 %+17.91%
100.28 %+4.86%
95.63 %-26.63%
130.34 %-3.75%
135.41 %+40.26%
96.54 %-10.05%
107.32 %+5.66%
101.57 %-0.07%
101.65 %-25.00%
135.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Capital Intensity Ratio of Health&Life Co is 181.67 % in 2025.

Capital Intensity Ratio of Health&Life Co changed from 115.70 % to 181.67 %, representing a 57.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Health&Life Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Health&Life Co

All Key Metrics — Health&Life Co